Discovering biological connections between experimental conditions based on common patterns of differential gene expression

BMC Bioinformatics

Volumn 12, Issue , 2011, Pages

  Gower, Adam C ^a   Spira, Avrum ^a,b   Lenburg, Marc E ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFFYMETRIX MICROARRAYS; BIOLOGICAL CONDITIONS; COMPUTATIONAL APPROACH; DIFFERENTIAL EXPRESSIONS; DIFFERENTIAL GENE EXPRESSIONS; EXPERIMENTAL CONDITIONS; GENE EXPRESSION DATA; GENE EXPRESSION SIGNATURES;

EXPERIMENTS; MICROARRAYS;

GENE EXPRESSION;

CKAP4 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MEMBRANE PROTEIN;

ALGORITHM; ARTICLE; BREAST TUMOR; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

ALGORITHMS; BREAST NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, ESTROGEN;

EID: 80053378461     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-12-381     Document Type: Article

References (63)

1. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, et al. Functional discovery via a compendium of expression profiles. Cell 2000, 102(1):109-126. 10.1016/S0092-8674(00)00015-5, 10929718.
2. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313(5795):1929-1935. 10.1126/science.1132939, 17008526.
3. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286(5439):531-537. 10.1126/science.286.5439.531, 10521349.
4. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, Gilman S, Dumas YM, Calner P, Sebastiani P, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007, 13(3):361-366. 10.1038/nm1556, 17334370.
5. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009. 10.1056/NEJMoa021967, 12490681.
6. McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010, 115(2):315-325. 10.1182/blood-2009-03-210732, 2808155, 19837975.
7. Chang JT, Nevins JR. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 2006, 22(23):2926-2933. 10.1093/bioinformatics/btl483, 17000751.
8. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4(5):3..
9. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
10. Hibbs MA, Hess DC, Myers CL, Huttenhower C, Li K, Troyanskaya OG. Exploring the functional landscape of gene expression: directed search of large microarray compendia. Bioinformatics 2007, 23(20):2692-2699. 10.1093/bioinformatics/btm403, 17724061.
11. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 2007, 23(23):3251-3253. 10.1093/bioinformatics/btm369, 17644558.
12. Chen R, Mallelwar R, Thosar A, Venkatasubrahmanyam S, Butte AJ. GeneChaser: identifying all biological and clinical conditions in which genes of interest are differentially expressed. BMC Bioinformatics 2008, 9:548. 10.1186/1471-2105-9-548, 2629779, 19094235.
13. Feng C, Araki M, Kunimoto R, Tamon A, Makiguchi H, Niijima S, Tsujimoto G, Okuno Y. GEM-TREND: a web tool for gene expression data mining toward relevant network discovery. BMC Genomics 2009, 10:411. 10.1186/1471-2164-10-411, 2748096, 19728865.
14. Vazquez M, Nogales-Cadenas R, Arroyo J, Botias P, Garcia R, Carazo JM, Tirado F, Pascual-Montano A, Carmona-Saez P. MARQ: an online tool to mine GEO for experiments with similar or opposite gene expression signatures. Nucleic Acids Res 2010, 38 Suppl:W228-W232.
15. Wu J, Qiu Q, Xie L, Fullerton J, Yu J, Shyr Y, George AL, Yi Y. Web-based interrogation of gene expression signatures using EXALT. BMC Bioinformatics 2009, 10:420. 10.1186/1471-2105-10-420, 2799423, 20003458.
16. Wen Z, Wang Z, Wang S, Ravula R, Yang L, Xu J, Wang C, Zuo Z, Chow MS, Shi L, et al. Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map. PLoS One 6(3):e18278.
17. Boyle JO, Gumus ZH, Kacker A, Choksi VL, Bocker JM, Zhou XK, Yantiss RK, Hughes DB, Du B, Judson BL, et al. Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev Res (Phila) 3(3):266-278.
18. Wang G, Ye Y, Yang X, Liao H, Zhao C, Liang S. Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PLoS One 6(1):e14573.
19. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006, 24(9):1151-1161. 10.1038/nbt1239, 16964229.
20. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004, 64(4):1522-1533. 10.1158/0008-5472.CAN-03-3326, 14973112.
21. Chang EC, Charn TH, Park SH, Helferich WG, Komm B, Katzenellenbogen JA, Katzenellenbogen BS. Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol 2008, 22(5):1032-1043. 10.1210/me.2007-0356, 2366177, 18258689.
22. Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 2008, 68(12):4910-4918. 10.1158/0008-5472.CAN-08-0303, 18559539.
23. Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR, Lessey BA, Giudice LC. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology 2007, 148(8):3814-3826. 10.1210/en.2006-1692, 17510236.
24. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA, et al. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology 2006, 147(3):1097-1121.
25. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999, 398(6729):708-713. 10.1038/19531, 10227293.
26. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999, 398(6729):714-718. 10.1038/19539, 10227294.
27. Rinne T, Brunner HG, van Bokhoven H. p63-associated disorders. Cell Cycle 2007, 6(3):262-268. 10.4161/cc.6.3.3796, 17224651.
28. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 2006, 66(15):7589-7597. 10.1158/0008-5472.CAN-06-2020, 16885358.
29. Roth RB, Hevezi P, Lee J, Willhite D, Lechner SM, Foster AC, Zlotnik A. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 2006, 7(2):67-80. 10.1007/s10048-006-0032-6, 16572319.
30. Martens JH, Kzhyshkowska J, Falkowski-Hansen M, Schledzewski K, Gratchev A, Mansmann U, Schmuttermaier C, Dippel E, Koenen W, Riedel F, et al. Differential expression of a gene signature for scavenger/lectin receptors by endothelial cells and macrophages in human lymph node sinuses, the primary sites of regional metastasis. J Pathol 2006, 208(4):574-589. 10.1002/path.1921, 16440291.
31. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, Wagner SN, Ramaswamy S, Mesirov JP, Hynes RO. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 2008, 6(5):760-769. 10.1158/1541-7786.MCR-07-0344, 2756991, 18505921.
32. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008, 1:13. 10.1186/1755-8794-1-13, 2408576, 18442402.
33. Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Mol Cancer Res 2005, 3(4):203-218.
34. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra JM, Jacquemier J, et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 2010,
35. Reischl J, Schwenke S, Beekman JM, Mrowietz U, Sturzebecher S, Heubach JF. Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol 2007, 127(1):163-169. 10.1038/sj.jid.5700488, 16858420.
36. O'Donnell RK, Kupferman M, Wei SJ, Singhal S, Weber R, O'Malley B, Cheng Y, Putt M, Feldman M, Ziober B, et al. Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene 2005, 24(7):1244-1251. 10.1038/sj.onc.1208285, 15558013.
37. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439(7074):353-357. 10.1038/nature04296, 16273092.
38. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA, Marks JR, Nevins JR. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001, 98(20):11462-11467. 10.1073/pnas.201162998, 58752, 11562467.
39. Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J, Dewhirst M, West M, Chi JT. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet 2008, 4(12):e1000293.. 2585811, 19057672.
40. Bourne TD, Bellizzi AM, Stelow EB, Loy AH, Levine PA, Wick MR, Mills SE. p63 Expression in olfactory neuroblastoma and other small cell tumors of the sinonasal tract. Am J Clin Pathol 2008, 130(2):213-218. 10.1309/TEDD2FCWH8W0H4HA, 18628089.
41. Brinck U, Ruschenburg I, Di Como CJ, Buschmann N, Betke H, Stachura J, Cordon-Cardo C, Korabiowska M. Comparative study of p63 and p53 expression in tissue microarrays of malignant melanomas. Int J Mol Med 2002, 10(6):707-711.
42. Lewis JS, Ritter JH, El-Mofty S. Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. Mod Pathol 2005, 18(11):1471-1481. 10.1038/modpathol.3800451, 15976812.
43. Reis-Filho JS, Simpson PT, Fulford LG, Martins A, Schmitt FC. P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms. Pathol Res Pract 2003, 199(12):785-793. 10.1078/0344-0338-00497, 14989490.
44. Sakiz D, Turkmenoglu TT, Kabukcuoglu F. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. Pathol Res Pract 2009, 205(9):589-594. 10.1016/j.prp.2009.01.010, 19577853.
45. Safe S, Wang F, Porter W, Duan R, McDougal A. Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms. Toxicol Lett 1998, (102-103):343-347.
46. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20(3):307-315. 10.1093/bioinformatics/btg405, 14960456.
47. Smyth GK, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor 2005, 397-420. New York: Springer.
48. Pollard KS, Gilbert HN, Ge Y, Taylor S, Dudoit S. multtest: Resampling-based multiple hypothesis testing. 2010,
49. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005, 33(20):e175.. 1283542, 16284200.
50. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30(1):207-210. 10.1093/nar/30.1.207, 99122, 11752295.
51. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264. 10.1093/biostatistics/4.2.249, 12925520.
52. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 1995, 57(1):289-300.
53. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13(11):3207-3214. 10.1158/1078-0432.CCR-06-2765, 17545524.
54. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102(38):13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
55. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 2010, 12(1):R5.. 2880423, 20064235.
56. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009, 11(5):R77. 10.1186/bcr2419, 2790859, 19874578.
57. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. IntJCancer 1998, 78(6):766-774.
58. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LC, et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. MolCancer Res 2009, 7(4):511-522.
59. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
60. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. MolCancer Ther 2004, 3(12):1585-1592.
61. Yoo JY, Lessor T, Hamburger AW. Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines. Breast Cancer ResTreat 1998, 51(1):71-81.
62. Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC. Further evidence to support the melanocytic origin of MDA-MB-435. MolPathol 2002, 55(5):294-299.
63. Wellcome Trust Sanger Institute, Cancer Genome Project, Cell Line Identity Typing. , http://www.sanger.ac.uk/genetics/CGP/Genotyping/synlinestable.shtml